^
    Back
    Association details:
    Biomarker:BRAF V600E
    Cancer:Melanoma
    Drug:ERAS-007 (ERK2 inhibitor, ERK1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Cell Reports Medicine
    Title:

    ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors

    Published date:
    07/21/2021
    Excerpt:
    ASN007 demonstrates activity in a BRAFV600E mutant melanoma tumor model that is resistant to BRAF and MEK inhibitors.
    DOI:
    10.1016/j.xcrm.2021.100350